Jointown Pharmaceutical Group and Lilly Asia Ventures were among the investors in the genetic sequencing technology developer's series A+ round.
US-based genetic diagnostics technology developer Singlera Genomics raised $60m yesterday in a series A+ round that included medical product distributor Jointown Pharmaceutical Group and pharmaceutical firm Eli Lilly.
Venture capital and private equity firm Green Pine Capital Partners and VC fund Prosperico Ventures co-led the round, which also featured UCF Medical Investment, a subsidiary of investment holding group UCF, while Eli Lilly invested through its Lilly Asia Ventures unit.
Founded in 2014, Singlera is developing DNA sequencing technology in order…